Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IONSBearishIndustry Newsnews

High materiality8/10

Novartis trial failures tare Ionis royalties amid pelacarsen setback

Sep 8, 2026, 8:37 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Pelacarsen's failed trial and Novartis' license actions raise questions on Ionis' royalty revenue and milestone potential; peer moves and large royalty exposure magnify downside risk in the near term.

AI summary

What happened, with direct paths to the underlying reporting

Novartis reported HARBOR DM1 failure for del-desiran and pelacarsen's Lp(a)HORIZON also missed benefits, though lowered Lp(a) levels were achieved. Ionis faces near-term pressure on royalty revenue from pelacarsen, tied to Novartis' global rights and Royalty Pharma's large stake; market reaction pressured IONS and related partners.

Novartis' HARBOR DM1 trial failed to meet the primary endpoint.
Pelacarsen Lp(a)HORIZON failed to reduce cardiovascular events.
Novartis owns global pelacarsen rights via a 2019 license with Avidity.
Ionis' royalties include Spinraza and pelacarsen; Royalty Pharma's $1.125B exposure.
NVS, IONS, and RPRX fall on the новости; premarket moves shown.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.